Alcohol Withdrawal Syndrome
Am Fam Physician. 2004 Mar 15;69(6):1443-1450.
The spectrum of alcohol withdrawal symptoms ranges from such minor symptoms as insomnia and tremulousness to severe complications such as withdrawal seizures and delirium tremens. Although the history and physical examination usually are sufficient to diagnose alcohol withdrawal syndrome, other conditions may present with similar symptoms. Most patients undergoing alcohol withdrawal can be treated safely and effectively as outpatients. Pharmacologic treatment involves the use of medications that are cross-tolerant with alcohol. Benzodiazepines, the agents of choice, may be administered on a fixed or symptom-triggered schedule. Carbamazepine is an appropriate alternative to a benzodiazepine in the outpatient treatment of patients with mild to moderate alcohol withdrawal symptoms. Medications such as haloperidol, beta blockers, clonidine, and phenytoin may be used as adjuncts to a benzodiazepine in the treatment of complications of withdrawal. Treatment of alcohol withdrawal should be followed by treatment for alcohol dependence.
In 1992, approximately 13.8 million Americans (7.4 percent of the U.S. adult population)1 met the criteria for alcohol abuse or dependence as specified in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR).2 In 2000, 226,000 patients were discharged from short-stay hospitals (excluding Veteran’s Affairs and other federal hospitals) with one of the following diagnoses: alcohol withdrawal (Table 1),2 alcohol withdrawal delirium, or alcohol withdrawal hallucinosis.3 It is estimated that only 10 to 20 percent of patients undergoing alcohol withdrawal are treated as inpatients,4 so it is possible that as many as 2 million Americans may experience symptoms of alcohol withdrawal conditions each year.
Alcohol withdrawal syndrome is mediated by a variety of mechanisms. The brain maintains neurochemical balance through inhibitory and excitatory neurotransmitters. The main inhibitory neurotransmitter is γ-amino-butyric acid (GABA), which acts through the GABA-alpha (GABA-A) neuroreceptor. One of the major excitatory neurotransmitters is glutamate, which acts through the N-methyl-D-aspartate (NMDA) neuroreceptor.
Alcohol enhances the effect of GABA on GABA-A neuroreceptors, resulting in decreased overall brain excitability. Chronic exposure to alcohol results in a compensatory decrease of GABA-A neuroreceptor response to GABA, evidenced by increasing tolerance of the effects of alcohol.
Diagnostic Criteria for Alcohol Withdrawal
A. Cessation of (or reduction in) alcohol use that has been heavy and prolonged.
B. Two (or more) of the following, developing within several hours to a few days after criterion A:
1. Autonomic hyperactivity (e.g., sweating or pulse rate greater than 100 beats per minute)
2. Increased hand tremor
4. Nausea or vomiting
5. Transient visual, tactile, or auditory hallucination s or illusions
6. Psychomotor agitation
8. Grand mal seizures
C. The symptoms in criterion B cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
D. The symptoms are not due to a general medical condition and are not better accounted for by another mental disorder.
Adapted with permission from American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, D.C.: American Psychiatric Association, 2000:216.
Alcohol inhibits NMDA neuroreceptors, and chronic alcohol exposure results in up-regulation of these receptors. Abrupt cessation of alcohol exposure results in brain hyperexcitability, because receptors previously inhibited by alcohol are no longer inhibited. Brain hyperexcitability manifests clinically as anxiety, irritability, agitation, and tremors. Severe manifestations include alcohol withdrawal seizures and delirium tremens.
An important concept in both alcohol craving and alcohol withdrawal is the “kindling” phenomenon; the term refers to long-term changes that occur in neurons after repeated detoxifications. Recurrent detoxifications are postulated to increase obsessive thoughts or alcohol craving.5 Kindling explains the observation that subsequent episodes of alcohol withdrawal tend to progressively worsen.
Although the significance of kindling in alcohol withdrawal is debated, this phenomenon may be important in the selection of medications to treat withdrawal. If certain medications decrease the kindling effect, they may become preferred agents.
The spectrum of withdrawal symptoms and the time range for the appearance of these symptoms after cessation of alcohol use are listed in Table 2. Generally, the symptoms of alcohol withdrawal relate proportionately to the amount of alcoholic intake and the duration of a patient’s recent drinking habit. Most patients have a similar spectrum of symptoms with each episode of alcohol withdrawal.
Minor withdrawal symptoms can occur while the patient still has a measurable blood alcohol level. These symptoms may include insomnia, mild anxiety, and tremulousness. Patients with alcoholic hallucinosis experience visual, auditory, or tactile hallucinations but otherwise have a clear sensorium.
Withdrawal seizures are more common in patients who have a history of multiple episodes of detoxification. Causes other than alcohol withdrawal should be considered if seizures are focal, if there is no definite history of recent abstinence from drinking, if seizures occur more than 48 hours after the patient’s last drink, or if the patient has a history of fever or trauma.
Alcohol withdrawal delirium, or delirium tremens, is characterized by clouding of consciousness and delirium. Episodes of delirium tremens have a mortality rate of 1 to 5 percent.6 Risk factors for developing alcohol withdrawal delirium include concurrent acute medical illness, daily heavy alcohol use, history of delirium tremens or withdrawal seizures, older age, abnormal liver function, and more severe withdrawal symptoms on presentation.
Evaluation of the Patient in Alcohol Withdrawal
The history and physical examination establish the diagnosis and severity of alcohol withdrawal. Important historical data include quantity of alcoholic intake, duration of alcohol use, time since last drink, previous alcohol withdrawals, presence of concurrent medical or psychiatric conditions, and abuse of other agents. In addition to identifying withdrawal symptoms, the physical examination should assess possible complicating medical conditions, including arrhythmias, congestive heart failure, coronary artery disease, gastrointestinal bleeding, infections, liver disease, nervous system impairment, and pancreatitis. Basic laboratory investigations include a complete blood count, liver function tests, a urine drug screen, and determination of blood alcohol and electrolyte levels.
Symptoms of Alcohol Withdrawal Syndrome
|Symptoms||Time of appearance after cessation of alcohol use|
Minor withdrawal symptoms: insomnia, tremulousness, mildanxiety, gastrointestinal upset, headache, diaphoresis, palpitations, anorexia
6 to 12 hours
Alcoholic hallucinosis: visual, auditory, or tactile hallucinations
12 to 24 hours*
Withdrawal seizures: generalized tonic-clonic seizures
24 to 48 hours†
Alcohol withdrawal delirium (delirium tremens): hallucinations (predominately visual), disorientation, tachycardia, hypertension, low-grade fever, agitation, diaphoresis
48 to 72 hours‡
*— Symptoms generally resolve within 48 hours.
†— Symptoms reported as early as two hours after cessation.
‡— Symptoms peak at five days.
The revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale is a validated 10-item assessment tool that can be used to quantify the severity of alcohol withdrawal syndrome, and to monitor and medicate patients going through withdrawal7,8 (Figure 1).7 CIWA-Ar scores of 8 points or fewer correspond to mild withdrawal, scores of 9 to 15 points correspond to moderate withdrawal, and scores of greater than 15 points correspond to severe withdrawal symptoms and an increased risk of delirium tremens and seizures.
In using the CIWA-Ar, the clinical picture should be considered because medical and psychiatric conditions may mimic alcohol withdrawal symptoms. In addition, certain medications (e.g., beta blockers) may blunt the manifestation of these symptoms.
Alcohol withdrawal syndrome can be confused with other conditions. Thyrotoxicosis, anticholinergic drug poisoning, and amphetamine or cocaine use can result in signs of increased sympathetic activity and altered mental status. Central nervous system infection or hemorrhage can cause seizures and mental status changes. Withdrawal from other sedative-hypnotic agents causes symptoms similar to those occurring in alcohol withdrawal syndrome.
Goals of Treatment
The American Society of Addiction Medicine lists three immediate goals for detoxification of alcohol and other substances: (1) “to provide a safe withdrawal from the drug(s) of dependence and enable the patient to become drug-free”; (2) “to provide a withdrawal that is humane and thus protects the patient’s dignity”; and (3) “to prepare the patient for ongoing treatment of his or her dependence on alcohol or other drugs.”6
Abnormalities in fluid levels, electrolyte levels, or nutrition should be corrected. Intravenous fluids may be necessary in patients with severe withdrawal because of excessive fluid loss through hyperthermia, sweating, and vomiting. Intravenous fluids should not be administered routinely in patients with less severe withdrawal, because these patients may become overhydrated.
Routine administration of magnesium sulfate has not been shown to improve withdrawal symptoms,9 but supplementation is appropriate if a patient is hypomagnesemic. Multivitamins and thiamine (100 mg per day) should be provided during treatment for alcohol withdrawal. If intravenous fluids are administered, thiamine (100 mg intravenously) should be given before glucose is administered, to prevent precipitation of Wernicke’s encephalopathy.
Medication can be administered using fixed-schedule or symptom-triggered regimens (Table 3).10 With a fixed-schedule regimen, doses of a benzodiazepine are administered at specific intervals, and additional doses of the medication are given as needed based on the severity of the withdrawal symptoms. In a symptom-triggered regimen, medication is given only when the CIWA-Ar score is higher than 8 points.
Assessment of Alcohol Withdrawal
Examples of Treatment Regimens for Alcohol Withdrawal
Monitoring (with no medication)
Monitor the patient by administering the CIWA-Ar (see Figure 1) every 4 to 8 hours until the score has been lower than 8 to 10 points for 24 hours.
Perform additional assessments as needed.
Administer the CIWA-Ar every hour to assess the patient’s need for medication.
Administer one of the following medications every hour when the CIWA-Ar score is at least 8 to 10 points:
Chlordiazepoxide (Librium), 50 to 100 mg
Diazepam (Valium), 10 to 20 mg
Lorazepam (Ativan), 2 to 4 mg
Administer one of the following medications every 6 hours:
Chlordiazepoxide, four doses of 50 mg, then eight doses of 25 mg
Diazepam, four doses of 10 mg, then eight doses of 5 mg
Lorazepam, four doses of 2 mg, then eight doses of 1 mg
Provide additional medication as needed when symptoms are not controlled (i.e., the CIWA-Ar score remains at least 8 to 10 points).
CIWA-Ar = Clinical Institute Withdrawal Assessment for Alcohol, revised.
Adapted with permission from Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997;278:148.
Symptom-triggered regimens have been shown to result in the administration of less total medication and to require a shorter duration of treatment.11,12 In one randomized, double-blind controlled trial,11 patients in the symptom-triggered group received an average of 100 mg of chlordiazepoxide, whereas patients in the fixed-schedule group received an average of 425 mg. The median duration of treatment in the symptom-triggered group was nine hours, compared with 68 hours in the fixed-schedule group. Patients were excluded from the study if they had concurrent medical or psychiatric illness requiring hospitalization or seizures from any cause.11
Another trial12 yielded similar results, with patients in the fixed-schedule group receiving an average of 231.4 mg of oxazepam and those in the symptom-triggered group receiving an average of 37.5 mg. Of the patients in the symptom-triggered group, 61 percent did not receive any oxazepam. This trial excluded persons with major psychiatric, cognitive, or medical comorbidities.
The use of symptom-triggered therapy requires training of the clinical staff. If this training has not been provided, fixed-schedule pharmacotherapy should be used.10
Choice of Treatment Setting
In most patients with mild to moderate withdrawal symptoms, outpatient detoxification is safe and effective, and costs less than inpatient treatment.4,13–15 However, certain patients should be considered for inpatient treatment regardless of the severity of their symptoms. Relative indications for inpatient alcohol detoxification are as follows: history of severe withdrawal symptoms, history of withdrawal seizures or delirium tremens, multiple previous detoxifications, concomitant psychiatric or medical illness, recent high levels of alcohol consumption, pregnancy, and lack of a reliable support network.16
If outpatient treatment is chosen, the patient should be assessed daily. The patient and support person(s) should be instructed about how to take the withdrawal medication, the side effects of the medication, the expected withdrawal symptoms, and what to do if symptoms worsen.6,17 Small quantities of the withdrawal medication should be prescribed at each visit; thiamine and a multivitamin also should be prescribed. Because close monitoring is not available in ambulatory treatment, a fixed-schedule regimen should be used.
Pharmacologic Treatment of Withdrawal
Pharmacologic treatment of alcohol withdrawal syndrome involves the use of medications that are cross-tolerant with alcohol. Benzodiazepines have been shown to be safe and effective, particularly for preventing or treating seizures and delirium, and are the preferred agents for treating the symptoms of alcohol withdrawal syndrome.10
The choice of agent is based on pharmacokinetics. Diazepam (Valium) and chlordiazepoxide (Librium) are long-acting agents that have been shown to be excellent in treating alcohol withdrawal symptoms. Because of the long half-life of these medications, withdrawal is smoother, and rebound withdrawal symptoms are less likely to occur. Lorazepam (Ativan) and oxazepam (Serax) are intermediate-acting medications with excellent records of efficacy. Treatment with these agents may be preferable in patients who metabolize medications less effectively, particularly the elderly and those with liver failure. Lorazepam is the only benzodiazepine with predictable intramuscular absorption (if intramuscular administration is necessary).
Rarely, it is necessary to use extremely high dosages of benzodiazepines to control the symptoms of alcohol withdrawal. Dosages of diazepam as high as 2,000 mg per day have been administered.18 Because clinicians often are reluctant to administer exceptionally high dosages, undertreatment of alcohol withdrawal is a common problem.
One randomized controlled trial (RCT)19 affirmed previous findings that carbamazepine is an effective alternative to benzodiazepines in the treatment of alcohol withdrawal syndrome in patients with mild to moderate symptoms. Patients in the study received 800 mg of carbamazepine on the first day, with the dosage tapered to 200 mg by the fifth day. Carbamazepine (Tegretol) also appears to decrease the craving for alcohol after withdrawal. It is not sedating and has little potential for abuse. Although carbamazepine is used extensively in Europe, its use in the United States has been limited by lack of sufficient evidence that it prevents seizures and delirium.
Several medications may be helpful adjuncts to benzodiazepines in the treatment of alcohol withdrawal syndrome. However, these medications should not be used as monotherapy.
Haloperidol (Haldol) can be used to treat agitation and hallucinations, although it can lower the seizure threshold. The use of atenolol (Tenormin) in conjunction with oxazepam has been shown to improve vital signs more quickly and to reduce alcohol craving more effectively than the use of oxazepam alone.20
Adjunctive treatment with a beta blocker should be considered in patients with coronary artery disease, who may not tolerate the strain that alcohol withdrawal can place on the cardiovascular system. Clonidine (Catapres) also has been shown to improve the autonomic symptoms of withdrawal.10 Although phenytoin (Dilantin) does not treat withdrawal seizures, it is an appropriate adjunct in patients with an underlying seizure disorder.
Treatment of alcohol withdrawal syndrome should be followed by treatment for alcohol dependence. Treatment of withdrawal alone does not address the underlying disease of addiction and therefore offers little hope for long-term abstinence.
In the outpatient setting, brief interventions are helpful in patients with alcohol abuse,21 but more intense interventions are required in patients with alcohol dependence. The anticonvulsant topiramate (Topamax) has been shown to be an effective adjunctive medication to decrease alcohol consumption and increase abstinence in alcohol-dependent patients.22
Some patients achieve dramatic results by joining 12-step groups such as Alcoholics Anonymous and Narcotics Anonymous. Other patients benefit from stays in comprehensive treatment facilities, which offer a combination of a 12-step model, cognitive-behavior therapy, and family therapy. The treatment of alcohol withdrawal syndrome should be supplemented by an individualized, comprehensive treatment program, or at least as many elements of such a program as the patient can tolerate and afford.
|Key clinical recommendation||Strength of recommendation||References|
The revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale is a validated 10-item assessment tool that can be used to quantify the severity of alcohol withdrawal syndrome, and to monitor and medicate patients going through withdrawal.
Symptom-triggered regimens have been shown to result in the administration of less total medication and to require a shorter duration of treatment.
In most patients with mild to moderate withdrawal symptoms, outpatient detoxification is safe and effective, and costs less than inpatient treatment.
Benzodiazepines have been shown to be safe and effective, particularly for preventing or treating seizures and delirium, and are the preferred agents for treating the symptoms of alcohol withdrawal syndrome.
Several medications have shown early promise in the treatment of alcohol withdrawal. In one case report23 involving five patients, a single 10-mg dose of baclofen resulted in relief of severe withdrawal symptoms. In a preliminary RCT,24 baclofen also reduced craving in alcohol-dependent patients.
Gabapentin, which is structurally similar to GABA, has been effective in the treatment of alcohol withdrawal in small studies.25,26 The low toxicity of gabapentin makes it a promising agent. In another study,27 the anticonvulsant agent vigabatrin, which irreversibly blocks GABA transaminase, improved withdrawal symptoms after only three days of treatment.
Early identification of problem drinking allows prevention or treatment of complications, including severe withdrawal. The U.S. Preventive Services Task Force28 recommends screening patients for problem drinking through a careful history or standardized screening questionnaire. Patients undergoing preoperative evaluation also should be screened, because alcohol withdrawal can complicate recovery from surgery.29 Elective surgery should be postponed until the dependent patient has not had alcohol for seven to 10 days.
1. Grant BF, Harford TC, Dawson DA, Chou P, Dufour M, Pickering R. NIAAA’s epidemiologic bulletin no. 35. Prevalence of DSM-IV alcohol abuse and dependence: United States, 1992. Alcohol Health Res World. 1994;18:243–8.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, D.C.: American Psychiatric Association, 2000:216.
3. Kozak LJ, Hall MJ, Owings MF. National Hospital Discharge Survey: 2000 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2002;153:1–194.
4. Abbott PJ, Quinn D, Knox L. Ambulatory medical detoxification for alcohol. Am J Drug Alcohol Abuse. 1995;21:549–63.
5. Malcolm R, Herron JE, Anton RF, Roberts J, Moore J. Recurrent detoxification may elevate alcohol craving as measured by the Obsessive Compulsive Drinking scale. Alcohol. 2000;20:181–5.
6. Kasser C, Geller A, Howell E, Wartenberg A. Detoxification: principles and protocols. American Society of Addiction Medicine. Accessed January 20, 2004, at: http://www.asam.org/publ/detoxification.htm.
7. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353–7.
8. Reoux JP, Miller K. Routine hospital alcohol detoxification practice compared to symptom triggered management with an Objective Withdrawal Scale (CIWA-Ar). Am J Addict. 2000;9:135–44.
9. Wilson A, Vulcano B. A double-blind, placebo-controlled trial of magnesium sulfate in the ethanol withdrawal syndrome. Alcohol Clin Exp Resp. 1984;8:542–5.
10. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;278:144–51.
11. Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA. 1994;272:519–23.
12. Daeppen JB, Gache P, Landry U, Sekera E, Schweizer V, Gloor S, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med. 2002;162:1117–21.
13. Hayashida M, Alterman AI, McLellan AT, O’Brien CP, Purtill JJ, Volpicelli JR, et al. Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med. 1989;320:358–65.
14. Hayashida M, Alterman A, McLellan T, Mann S, Maany I, O’Brien C. Is inpatient medical alcohol detoxification justified: results of a randomized, controlled study. NIDA Res Monogr. 1988;81:19–25.
15. Stockwell T, Bolt L, Milner I, Russell G, Bolderston H, Pugh P. Home detoxification from alcohol: its safety and efficacy in comparison with inpatient care. Alcohol Alcohol. 1991;26:645–50.
16. Myrick H, Anton RF. Treatment of alcohol withdrawal. Alcohol Health Res World. 1998;22:38–43.
17. Myrick H, Anton RF. Clinical management of alcohol withdrawal. CNS Spectr. 2000;5:22–32.
18. Wolf KM, Shaughnessy AF, Middleton DB. Prolonged delirium tremens requiring massive doses of medication. J Am Board Fam Pract. 1993;6:502–4.
19. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002;17:349–55.
20. Horwitz RI, Gottlieb LD, Kraus ML. The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome. Results of a randomized clinical trial. Arch Intern Med. 1989;149:1089–93.
21. Fleming MF, Barry KL, Manwell LB, Johnson K, London R. Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices. JAMA. 1997;277:1039–45.
22. Johnson BA, AitDaoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677–85.
23. Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med. 2002;112:226–9.
24. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37:504–8.
25. Myrick H, Malcolm R, Brady KT. Gabapentin treatment of alcohol withdrawal [Letter]. Am J Psychiatry. 1998;155:1632.
26. Bozikas V, Petrikis P, Gamvrula K, Savvidou I, Karavatos A. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:197–9.
27. Stuppaeck CH, Deisenhammer EA, Kurz M, Whitworth AB, Hinterhuber H. The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome. Alcohol Alcohol. 1996;31:109–11.
28. U.S. Preventive Services Task Force. Screening for problem drinking. In: Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2d ed. Baltimore: Williams & Wilkins, 1996. Accessed January 20, 2004, at: http://hstat.nlm.nih.gov/hq/Hquest/db/local.gcps.cps/screen/Browse/s/64610/cmd/HF/action/GetText?IHR=CH52.
29. Chang PH, Steinberg MB. Alcohol withdrawal. Med Clin North Am. 2001;85:1191–212.
Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.